Compare CVS Health Corp (CVS) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? CVS Health Corp trades at $86.81 (market cap $112.29B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $24.8 (market cap $4.93B). The key difference: CVS Health Corp is far larger — about 22.8× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and CVS Health Corp pays a 3.03% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and VanEck JP Morgan EM Local Currency Bond ETF for 38 Days on average.
| CVS | EMLC | |
|---|---|---|
Market Cap | $112.29B | $4.93B |
Volume | 7,763,676 | 2,843,860 |
Sector | Health | Fixed Income |
52-Week High | $110.60 | $26.59 |
52-Week Low | $70.08 | $24.53 |
Typical Hold Time | 83 Days | 38 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
EMLC trades at $24.77, down 0.24% on the day and hitting a new 52-week low. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though emerging market bonds have shown relative outperformance in 2026. Recent dividends of $0.14 and $0.13 were declared for October and August 2026 respectively.
The outlook remains cautious as dollar strength and rising global bond yields create challenges for emerging market local currency debt. While diversification benefits exist, near-term performance depends on currency dynamics and Federal Reserve policy direction. Key risks include currency volatility and global interest rate movements affecting bond valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
